CTI BioPharma Income Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	73.13	73.13	85.15	46.71	-	-
Other Revenue	-3.23	-	-	-	23.36	0.23
Revenue	69.9	73.13	85.15	46.71	23.36	0.23
Revenue Growth (YoY)	-21.61%	-14.11%	82.30%	99.92%	10283.64%	-
Cost of Revenue	59.19	61.51	66.89	50.23	17.88	0.41
Gross Profit	10.71	11.62	18.26	-3.52	5.48	-0.18
Other Operating Expenses	37.81	36.37	34.67	11.17	13.08	8.29
Operating Expenses	109.35	108.21	98.65	29.58	23.67	8.29
Operating Income	-98.64	-96.58	-80.39	-33.11	-18.19	-8.47
Interest Expense	-3.91	-3.54	-2.7	-0.85	-2.02	-0.04
Interest & Investment Income	0.58	0.59	0.79	0.43	-	0.01
Other Non Operating Income (Expenses)	-0.01	-0.15	-4.84	-0.03	0.02	0.11
Pretax Income	-101.97	-99.69	-87.13	-33.55	-20.2	-8.4
Income Tax Expense	-2.3	-1.97	-0.81	-1.82	-0.66	-
Earnings From Continuing Operations	-99.68	-97.72	-86.32	-31.74	-19.54	-8.4
Earnings From Discontinued Operations	-	-	-	-	-0.08	-4.03
Net Income	-99.68	-97.72	-86.32	-31.74	-19.63	-12.43
Net Income to Common	-99.68	-97.72	-86.32	-31.74	-19.63	-12.43
Shares Outstanding (Basic)	-	233	180	-	119	-
Shares Outstanding (Diluted)	-	233	180	-	119	-
Shares Change (YoY)	-	28.89%	-	-	-	-
EPS (Basic)	-	-0.42	-0.48	-	-0.16	-
EPS (Diluted)	-	-0.42	-0.48	-	-0.16	-
Gross Margin	15.33%	15.89%	21.45%	-7.54%	23.46%	-81.33%
Operating Margin	-141.12%	-132.07%	-94.41%	-70.88%	-77.88%	-3766.22%
Profit Margin	-142.60%	-133.62%	-101.38%	-67.95%	-84.00%	-5523.56%
EBITDA	-55.03	-52.67	-16.41	-14.7	-7.6	-4.44
EBITDA Margin	-78.72%	-72.02%	-19.28%	-31.47%	-32.53%	-
D&A For EBITDA	43.61	43.91	63.97	18.41	10.59	4.03
EBIT	-98.64	-96.58	-80.39	-33.11	-18.19	-8.47
EBIT Margin	-141.12%	-132.07%	-94.41%	-70.88%	-77.88%	-
Revenue as Reported	69.9	73.13	85.15	46.71	23.36	0.23

Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.